TARA Stock Overview
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Protara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.79 |
| 52 Week High | US$5.24 |
| 52 Week Low | US$1.04 |
| Beta | 1.92 |
| 1 Month Change | -4.62% |
| 3 Month Change | -37.58% |
| 1 Year Change | -2.11% |
| 3 Year Change | -70.22% |
| 5 Year Change | n/a |
| Change since IPO | -90.70% |
Recent News & Updates
Recent updates
Protara: A Bombed Out Biotech With A Very Positive Skew
Feb 22Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Dec 16
We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth
Apr 22The Prognosis For Protara Therapeutics
Oct 13Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Sep 12Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
Mar 21Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?
Dec 06Shareholder Returns
| TARA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.8% | -2.9% | -0.6% |
| 1Y | -2.1% | 6.6% | 25.4% |
Return vs Industry: TARA underperformed the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: TARA underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| TARA volatility | |
|---|---|
| TARA Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TARA's share price has been volatile over the past 3 months.
Volatility Over Time: TARA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 27 | Jesse Shefferman | www.protaratx.com |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition.
Protara Therapeutics, Inc. Fundamentals Summary
| TARA fundamental statistics | |
|---|---|
| Market cap | US$57.65m |
| Earnings (TTM) | -US$42.47m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs TARA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TARA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.47m |
| Earnings | -US$42.47m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.06 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TARA perform over the long term?
See historical performance and comparison